Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

被引：0
|
作者：
Xiang Zhang
Lotte C. A. Stiekema
Erik S. G. Stroes
Albert K. Groen
机构：
[1] Amsterdam University Medical Center,Department of Experimental Vascular Medicine
[2] University of Amsterdam,Human and Animal Physiology
[3] Wageningen University,Department of Vascular Medicine
[4] Amsterdam University Medical Center,undefined
[5] University of Amsterdam,undefined
来源：
Lipids in Health and Disease | / 19卷
关键词：
PCSK9 antibodies; Evolocumab; Lipoprotein(a); Metabolomics; VLDL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
    Zhang, Xiang
    Stiekema, Lotte C. A.
    Stroes, Erik S. G.
    Groen, Albert K.
    LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)
  • [2] PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
    Blom, Dirk J.
    Dent, Ricardo
    Castro, Rita C.
    Toth, Peter P.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 185 - 197
  • [3] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
    Shapiro, Michael D.
    Tavori, Hagai
    Oleaga, Carlota
    Miles, Joshua
    Fazio, Sergio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [4] Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects
    Rosenson, Robert S.
    Tate, Ashley
    Mar, Phyu
    Grushko, Olga
    Chen, Qinzhong
    Goonewardena, Sascha N.
    ATHEROSCLEROSIS, 2024, 392
  • [5] Lipoprotein (a) Evolocumab (PCSK9) effectively lowers Lp(a)-, LDL- and ApolipoB Levels
    Schulz-Hanke, Ines
    AKTUELLE KARDIOLOGIE, 2014, 3 (06) : 340 - 340
  • [6] Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
    Afanasieva, Olga
    Ezhov, Marat, V
    Klesareva, Elena
    Razova, Oksana
    Chubykina, Uliana
    Egiazaryan, Mane
    Sherstyuk, Ekaterina
    Afanasieva, Marina
    Utkina, Elena
    Pokrovsky, Sergei
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2020, 7 (04) : 1 - 11
  • [7] Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9
    Desai, Nihar
    Giugliano, Robert
    Wasserman, Scott
    Gibbs, John
    Liu, Thomas
    Scott, Robert
    Sabatine, Marc
    CIRCULATION, 2014, 130
  • [8] PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
    Pirillo, Angela
    Catapano, Alberico Luigi
    EUROPEAN HEART JOURNAL, 2018, 39 (27) : 2586 - 2588
  • [9] PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
    Raal, Frederick J.
    Giugliano, Robert P.
    Sabatine, Marc S.
    Koren, Michael J.
    Blom, Dirk
    Seidah, Nabil G.
    Honarpour, Narimon
    Lira, Armando
    Xue, Allen
    Chiruvolu, Padmaja
    Jackson, Simon
    Di, Mei
    Peach, Matthew
    Somaratne, Ransi
    Wasserman, Scott M.
    Scott, Rob
    Stein, Evan A.
    JOURNAL OF LIPID RESEARCH, 2016, 57 (06) : 1086 - 1096
  • [10] Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
    Kasichayanula, Sreeneeranj
    Grover, Anita
    Emery, Maurice G.
    Gibbs, Megan A.
    Somaratne, Ransi
    Wasserman, Scott M.
    Gibbs, John P.
    CLINICAL PHARMACOKINETICS, 2018, 57 (07) : 769 - 779
12345